The SPC Blog has received another question from a reader:"Is anyone aware of any other cases in Europe other than the Flufacenet case in France and the Sumatriptan case in Germany relating to the national patent offices granting SPCs with narrower product descriptions than the applicant requested, and where the patent office was then asked to re-examine the case? Moreover, does someone have an English translation of the Sumatriptan case that can be shared?"
If anyone has knowledge about other cases, please post your information as a comment below.
No comments:
Post a Comment